Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma

NCT03837509 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03837509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03837509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
September 25, 2019
Completion date
April 5, 2022
Enrollment
15 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma